1932

Abstract

In spite of forty years of effective chemotherapy for tuberculosis, the molecular mechanisms of antibacterial compounds in have only recently been revealed. Broad spectrum antibacterials, including streptomycin, rifampicin, and fluoroquinolones have been demonstrated to act on the same targets in as they do in . Resistance to these agents results from single mutagenic events that lead to amino acid substitutions in their target proteins. The mechanisms of action of the unique antitubercular drugs, including isoniazid, ethambutol, and pyrazinamide have also recently been defined. Resistance to isoniazid can be caused either by mutations in the G-encoded catalase-peroxidase, the enzyme responsible for drug activation, or by the molecular target, the -encoded long chain enoyl-ACP reductase. Ethambutol appears to block specifically the biosynthesis of the arabinogalactan component of the mycobacterial cell envelope, and pyrazinamide has no known target. With the resurgence of tuberculosis and the appearance of strains which are multiply resistant to the above compounds, present tuberculosis chemotherapies are threatened. New approaches to the treatment of multi drug-resistant tuberculosis are needed.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.bi.65.070196.001243
1996-07-01
2024-06-20
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.bi.65.070196.001243
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error